EHA 2023 | Treatment options for patients with TP53-mutated AML
Michael Loschi, MD, PhD, University Hospital of Nice, Cote d’Azur University, Nice, France, describes the treatments available for patients with TP53-mutated acute myeloid leukemia (AML). Dr Loschi comments on the benefits of encouraging patients to enroll in clinical trials, before discussing treatment options before and after allogeneic stem cell transplantation (alloSCT). This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honorarium: Novartis, Gilead, Pfizer, Sobi, BMS, Abbvie, Janssen, Astrazeneca, Alexion, GSK, Incyte, Morphosys, Telios, Kartos
